Introduction
============

Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia [@b1],[@b2]. However, it is a rare disease in most countries including Japan [@b3]. Because of anatomical features, NPC is not suitable for surgery. In addition, the majority of NPC which has wild-type p53 is highly radiosensitive [@b4]. Thus, radiotherapy (RT) plays a central role in the locoregional control of NPC [@b5],[@b6]. Another characteristic of NPC is that distant metastasis is more common than it is in other carcinomas of the head and neck. Therefore, chemotherapy plays an important role in improving treatment outcomes.

In 1998, the American Intergroup 0099 study (IGS 0099), which used three courses each of concurrent chemotherapy (cisplatin \[CDDP\], 100 mg/m^2^) and adjuvant chemotherapy (AC) (CDDP, 80 mg/m^2^ and 5-fluorouracil \[5-FU\], 4000 mg/m^2^ per 4 days), was the first study to demonstrate significant improvements in the overall survival (OS) compared with RT alone [@b7]. However, issues have arisen with this treatment method. A higher incidence of adverse events of Grade 3 or higher has been observed in the chemoradiation group than in the radiation alone group (59% vs. 34%). Approximately, about 55% underwent the full course of AC. As a result, chemotherapy reduced distant metastasis. However, it might not be sufficient.

In the Aichi Cancer Center, we conducted alternating chemoradiotherapy (ALCRT) with three courses of FP (5-FU and CDDP) in patients with locally advanced NPC from 1987 and reported promising results with a better compliance [@b8],[@b9]. Considering these results, a phase II study in which 25 facilities participated was initiated in December 2003.

The present study was to evaluate the long-term outcomes and to assess the usefulness of ALCRT in patients with NPC.

Materials and Methods
=====================

Eligible patient for this study was as follows, histologically-proven WHO type I to III NPC, clinical stage IIB-IVB (2003 TNM), age 18--70 year old with a performance score of 0--2 (Eastern Cooperative Oncology Group), WBC count ≥ 3000/mm^3^, neutrophil ≥ 1500/mm^3^, platelet count ≥ 100,000 mm^3^, hemoglobin ≥ 10 g/dL, total bililubin ≤ 2.0 mg/dL, creatinine clearance ≥ 60 mL/min, without physical and mental diseases that were obstacle to receive the protocol therapy, and approved by the Ethics Committee of each facility.

The patients with active multiple cancer, history of radiotherapy and/or surgery for head and neck cancer, obvious infectious diseases, and history of severe drug allergy, were excluded from registration. Extend of disease evaluation included a fiberscopic examination of upper-airway from nose to hypopharynx, chest X-P, liver ultrasonography or CT, bone scan, computed tomography (CT) scan and magnetic resonance image (MRI) scan of the nasopharynx, skullbase, and neck. All patients were required to provide written informed consent before registration.

Alternating chemoradiotherapy
-----------------------------

The treatment scheme is shown in Figure[1](#fig01){ref-type="fig"}. 5FU at a dose of 800 mg/m^2^ per 24 h was administered intravenously for a 120-h infusion, followed by a 24 h infusion of CDDP at a dose of 100 mg/m^2^ per 24 h (day 6). During the course of ALCRT, chemotherapy was performed before RT, and RT (Field A) was then performed for 4 weeks beginning 2--3 days after the completion of chemotherapy. The second course of chemotherapy was performed 2--3 days after the completion of RT. The second course of RT (Field B) was then performed with a reduced irradiation field 2--3 days after the second chemotherapy. Furthermore, the third course of chemotherapy was performed 2--3 days after the completion of the second course of RT.

![Study design of alternating chemoradiotherapy. 5FU: 5-fluorouracil; 800 mg/m^2^ per day i.v. continuous infusion × 5 days (day 1--5); CDDP: cisplatin, 100 mg/m^2^ per day i.v. continuous infusion (day 6); Field A: large field (from the skull base to the supraclavicular fossa), 1.8 Gy/f, 5 f/w, total tumor dose; 36 Gy; Field B: shrinking field, 2 Gy/f, 5 f/w, total tumor dose; 34 Gy. The interval between Field A and Field B is 10--12 days.](cam40004-1186-f1){#fig01}

Chemotherapy was not performed when serum creatinine levels exceeded 1.5 mg/dL at the scheduled date of chemotherapy. In addition, chemotherapy was postponed for the patients with WBC counts \<3000/mm^2^ or platelet counts \< 75,000/mm^2^ at the scheduled date of chemotherapy. Moreover, when the patients did not meet the above hematologic criteria (WBC counts ≥ 3000/mm^2^ and platelet counts ≥ 75,000/mm^2^) more than 6 weeks after the last day of previous chemotherapy, the administration of chemotherapy was abandoned. When the WBC counts were \<1000/mm^2^ or the platelet counts were \<25,000/mm^2^ after chemotherapy, the doses of 5-FU and CDDP were reduced by 25% at the next administration. The doses of CDDP could be reduced by 25% when serum creatinine levels temporarily exceeded 1.5 mg/dL, the dose of the next CDDP administration alone was decreased by 25%.

Using a 6-MV photon beam by linear accelerator, RT was performed with a daily fraction of 1.8 Gy from day 10 to 37 and 2 Gy from day 49 to 71. The initial radiation field covered between the nasopharynx and middle cervical region, using bilateral opposing portals and between lower cervical and supraclavicular regions using the anterior single field irradiation at a dose of 36 Gy/20 fraction. Then, a shrinking field of 34 Gy/17 fraction was boosted to the nasopharynx using the dynamic conformal rotational technique or bilateral opposing portals. In the cervical lymph nodes in which metastases were detected during the initial examination, 34 Gy of 6-MV photon beam or electron beam in 17 fractions was additionally irradiated (Field B). The dose of irradiation to the spinal cord, optic chiasm, and brain was limited to less than 40 Gy, 48 Gy, and 56 Gy, respectively.

Neck dissection was allowed to be performed on patients with progressive nodal disease or disease persistence.

Patient assessments
-------------------

According to the National Cancer Institute-Common Toxicity Criteria ver. 3.0, the toxicity of this ALCRT was evaluated. The antitumor effects of were evaluated 1 month after the completion of this treatment, according to the Response Evaluation Criteria in Solid Tumors (RECIST).

Patients were assessed every 2 months during the first year, every 3 months for the subsequent 2 years, and every 4--6 months thereafter. Locoregional recurrences were assessed by physical examination, a fiberscopic examination, biopsy, and MRI and/or CT. Distant metastases were assessed by chest X-P, liver ultrasonography or CT, and bone scan.

Continuous and categorical variables are presented as medians with ranges and as frequencies with percentages, respectively. OS, progression-free survival (PFS), locoregional recurrence-free (LRF), and distant metastasis-free (DMF) curves were estimated using the Kaplan--Meier method. In univariate analysis, potential factors associated with each of OS, PFS, LRF, and DMF were explored using the log-rank test. In multivariate analysis, the factors that were found to have values of *P* \< 0.1 in the log-rank analysis were included in the Cox proportional-hazards regression model. The results are summarized as hazard ratios, 95% confidence intervals, and *P*-values, based on the Cox regression. All P values were two-sided, and *P* \< 0.05 was considered statistically significant. Statistical analyses were performed using R (version 3.1.1, Vienna, Austria).

Results
=======

Ninety eligible patients with NPC were enrolled in this study between December 2003 and March 2006, and 88 patients were finally enrolled, excluding two patients with heart disease and patient refusal. Furthermore, distant metastasis was diagnosed in one patient with the imaging performed during the first chemotherapy, and this patient underwent treatment, according to the protocol. We then evaluated the adverse effects in these 88 patients and the tumor response and survival periods in 87 patients, excluding the distant metastasis case. The patient characteristics were shown in Table[1](#tbl1){ref-type="table"}.

###### 

Patient characteristics

  Characteristic                      Number of patients (%)
  ----------------------------------- ------------------------
  Performance status                  
   0                                  74 (84.1)
   1                                  12 (13.6)
   2                                  2 (2.3)
  Gender                              
   Male                               67 (76.1)
   Female                             21 (23.9)
  Stage                               
   II B                               22 (25.0)
   T1N1M0: 11, T2aN1M0: 5,            
   T2bN1M0: 6                         
   III                                36 (40.9)
   T1N2M0: 13, T2bN2M0: 9,            
   T3N0M0: 3 T3N1M0: 2, T3N2M0: 9     
   IV A                               16 (18.2)
   T4N0M0: 3, T4N1M0: 3, T4N2M0: 10   
   IV B                               13 (14.8)
   T1N3M0: 6, T2aN3M0: 1, T2bN3M0:    
   1 T3N3M0: 2, T4N3M0: 3             
   IV C                               1 (1.1)
   T3N2M1: 1                          
  Histology                           
   WHO type I                         18 (20.5)
   WHO type II                        32 (36.4)
   WHO type III                       38 (43.2)

Thirteen patients (14.8%) discontinued treatment for the following reasons: unable to continue treatment due to deterioration in the general physical condition (three patients), patient refusal (five patients), responsible physician's judgment (four patients), and unknown (one patient). Patients were considered to have completed the course of treatment if they were administered at least 70% of both the medication and radiological doses. As a result, a total of 80 patients (91%) completed the radiation therapy, and a total of 67 patients (76.1%) completed the course of treatment. The total tumor dose ranged from 36 to 76 Gy (median: 70 Gy, mean: 69.38 Gy) in the nasopharynx and from 36 to 76 Gy (median: 66 Gy, mean: 64.28 Gy) in the metastatic cervical lymph nodes. The total 5-FU dose ranged from 3380 to 12,669 mg/m^2^ (median: 12,000 mg/m^2^, mean: 10,800 mg/m^2^), and the total CDDP dose ranged from 100 to 306 mg/m^2^ (median: 300 mg/m^2^, mean: 267.5 mg/m^2^). Furthermore, the total duration of RT ranged from 35 to 127 days (median: 66 days), and the overall treatment time (OTT) of ALCRT ranged from 7 to 114 days (median: 87 days). The median follow-up duration for all 88 patients was 67 months (range: 3--91 months) by March 2012.

Toxicity
--------

The acute toxicities were shown in Table[2](#tbl2){ref-type="table"}. The major acute adverse effects of \>Grade 3 were as follows: anorexia in 42 patients (47.7%), leukocytopenia in 40 patients (45.5%), and mucositis in 28 patients (31.8%).

###### 

Acute adverse effects

                           Toxicity grade (number of patients), *n* = 88                  
  ------------------------ ----------------------------------------------- ---- ---- ---- ---
  Hematologic                                                                             
   White blood cell        3                                               9    36   38   2
   Neutrophil              22                                              9    37   20   0
   Platelet                31                                              35   18   5    2
   Hemoglobin              7                                               32   32   12   5
   GOT                     52                                              30   5    1    0
   GPT                     33                                              44   10   1    0
   Creatinine              52                                              24   12   0    0
  Nonhematologic                                                                          
   Allergic reaction       84                                              1    3    0    0
   Hearing                 77                                              0    9    2    0
   Fever                   81                                              0    3    4    0
   Infection               4                                               15   35   28   5
   Loss of hair            55                                              32   1    0    0
   Anorexia                7                                               18   20   42   0
   Diarrhea                62                                              9    15   2    0
   Dry mouth               25                                              27   23   13   0
   Mucositis               12                                              14   34   28   0
   Nausea                  4                                               22   39   23   0
   Vomiting                33                                              16   29   10   0
   Neurological disorder   86                                              1    0    0    0

The main late toxicities were shown in Table[3](#tbl3){ref-type="table"}. The late adverse effects of \>Grade 2 were as follows: dry mouth in 32 patients (36.3%), mucosal damage in 9 patients (10.2%), cervical cellulitis in 1 patient (1.1%), infection of the middle ear in 1 patient, and hearing loss in 1 patient.

###### 

Late adverse effects

                            Toxicity grade (number of patients), *n *= 88                 
  ------------------------- ----------------------------------------------- ---- ---- --- ---
  Temporomandibular joint   87                                              1    0    0   0
  Mucosa                    55                                              14   8    1   0
  Dry mouth                 39                                              17   30   2   0
  Skin                      77                                              10   0    0   0
  Subcutaneous tissue       86                                              1    1    0   0
  Infection                                                                               
   Cervical cellulitis      87                                              0    0    1   0
   Otitis media             87                                              0    1    0   0
  Hearing                   86                                              1    1    0   0
  Brain necrosis            87                                              1    0    0   0

Treatment outcome
-----------------

A complete response was achieved in 54 patients (62.0%), a partial response in 26 patients (29.9%), a stable disease in 4 patients, an unevaluated response in 1 patient, and an unknown in 2 patients. The initial recurrent sites were the nasopharynx in 12 patients, the regional lymph nodes in 3 patients, and distant metastasis in 12 patients. Table[4](#tbl4){ref-type="table"} shows the initial recurrent sites, according to the histopathological findings.

Until March 2012, 61 patients (70.1%) were alive, and 59 of these 61 remain cancer free. Twelve patients died of local recurrence, 12 patients died of distant metastases, and 2 patients died of unrelated causes without cancer. The OS and PFS curves are shown in Figure[2](#fig02){ref-type="fig"}. The 5 year OS and PFS rates were estimated to be 78.04% (95% CI, 69.1--87.0%) and 68.74% (95% CI, 58.8--78.7%), respectively).

###### 

Initial recurrent sites according to WHO histology

                      Initial recurrent sites                 
  ------------------- ----------------------------------- --- ---
  Type I *n* = 18     4                                   2   0
  Type II *n* = 32    4                                   1   6
  Type III *n* = 37   4[1](#tf4-1){ref-type="table-fn"}   0   6

One case was maxillary sinus which was out of RT field.

![Actuarial survival rates in all 87 patients with nasopharyngeal carcinoma by Kaplan--Meier method. (A) A solid line: overall survival curve. A broken line: 95% confidence interval. (B) A solid line: progression-free survival curve. A broken line: 95% confidence interval.](cam40004-1186-f2){#fig02}

Factors involved in the overall survival and progression-free survival time (Tables[6](#tbl6){ref-type="table"})
----------------------------------------------------------------------------------------------------------------

###### 

Results of the univariate analysis of prognostic factors on overall and progression-free survival

                                                         Overall survival   Progression-free survival                                    
  ------------------------------------- ---------------- ------------------ --------------------------- -------- ------- --------------- --------
  Age                                   \<50 (36)        1                  0.732--3.476                0.5097   1       0.582--2.826    0.5368
                                        ≥50 (60)         1.367                                                   1.282                   
  Gender                                Male (66)        1                  0.732--3.476                0.0937   1       0.049--0.873    0.0176
                                        Female (21)      0.306                                                   0.206                   
  TNM primary                           1 or 2 (52)      1                  0.463--2.866                0.7609   1       0.913--4.272    0.0781
                                        3 or 4 (35)      1.159                                                   1.975                   
  TNM LN                                0 or 1 (33)      1                  1.688--94.785               0.0014   1       2.124--38.12    0.0003
                                        2 or 3 (54)      12.647                                                  8.998                   
  Stage                                 II or III (58)   1                  0.6103--3.779               0.3656   1       0.878--4.110    0.0975
                                        IV (29)          1.518                                                   1.900                   
  WHO pathology                         I (18)           1                  0.301--2.745                0.8669   1       0.305--1.895    0.556
                                        II or III (69)   0.910                                                   0.761                   
  PS                                    0 (73)           1                  0.125--2.370                0.4109   1       0.470--3.3090   0.6561
                                        1 or 2 (14)      0.545                                                   1.248                   
  RT dose primary                       \<70 (5)         1                  0.1518--8.583               0.8989   1       0.172--3.84     0.6654
                                        ≥70 (81)         1.1140                                                  0.728                   
  RT dose lymph node                    \<70 (21)        1                  0.591--11.072               0.1927   1       0.504--3.545    0.5585
                                        ≥70 (65)         2.558                                                   1.337                   
  Total dose of 5-FU                    \<12,000 (37)    1                  0.140--0.903                0.0230   1       0.162--0.789    0.0078
                                        ≥12,000 (50)     0.355                                                   0.357                   
  Total dose of CDDP                    \<300 (38)       1                  0.232--1.411                0.4560   1       0.205--0.974    0.0375
                                        ≥300 (49)        0.573                                                   0.447                   
  OTT[2](#tf5-2){ref-type="table-fn"}   \<87 (38)        1                  0.191--1.273                0.1361   1       0.261--1.2691   0.1656
                                        ≥87 (47)         0.494                                                   0.576                   

Hazard ratio.

Overall treatment time.

###### 

Results of the multivariate analysis of prognostic factors on overall and progression-free survival

                                         Overall survival   Progression-free survival                                    
  -------------------- ----------------- ------------------ --------------------------- -------- ------- --------------- --------
  Gender               Male (66)         1                  0.074--1.404                0.1316   1       0.049--0.910    0.0369
                       Female (21)       0.322                                                   0.211                   
  TNM primary          1 or 2 (52)                                                               1       0.781--3.985    0.1741
                       3 or 4 (35)                                                               1.765                   
  TNM LN               0 or 1 (33)       1                  0.097--1.353                0.0243   1       1.453--27.946   0.0141
                       2 or 3 (54)       10.267                                                  6.372                   
  Stage                IIB or III (58)                                                           1       0.517--2.774    0.6734
                       IV (29)                                                                   1.198                   
  Total dose of 5-FU   \<12,000 (37)     1                  0.155--1.012                0.0531   1       0.162--1.015    0.0539
                       ≥12,000 (50)      0.396                                                   0.406                   
  Total dose of CDDP   \<300 (38)                                                                1       0.358--2.181    0.7889
                       ≥300 (49)                                                                 0.884                   

Hazard ratio.

In the univariate analysis, N classification and total 5-FU dose had significant impacts on OS. In the multivariate analysis, N classification had a significant impact on OS.

In the univariate analysis, gender, N classification, total 5-FU dose, and total CDDP dose had significant impacts on PFS. In the multivariate analysis, gender and N classification had significant impacts on PFS.

Factors involved in the locoregional recurrence-free and distant metastasis-free rates (Tables[8](#tbl8){ref-type="table"})
---------------------------------------------------------------------------------------------------------------------------

###### 

Results of the univariate analysis of prognostic factors on locoregional and distant metastasis-free rates

                                                          Locoregional-free rate   Distant metastasis-free rate                                    
  ------------------------------------- ----------------- ------------------------ ------------------------------ -------- ------- --------------- --------
  Age                                   \<50 (36)         1                        0.4715--5.200                  0.4604   1       0.330--3.278    0.9462
                                        ≥50 (50)          1.566                                                            1.040                   
  Gender                                Male (66)         1                        0, infty                       0.0303   1       0.116--2.417    0.4037
                                        Female (21)       Near 0                                                           0.529                   
  TNM primary                           1 or 2 (52)       1                        0.956--10.548                  0.0464   1       0.492--4.735    0.4602
                                        3 or 4 (35)       3.175                                                            1.527                   
  TNM LN                                0 or 1 (33)       1                        0.761--15.925                  0.0866   1       0, infty        0.0032
                                        2 or 3 (54)       3.482                                                            Infty                   
  Stage                                 IIB or III (58)   1                        0.318--3.518                   0.9262   1       1.390--15.379   0.0060
                                        IV (29)           1.058                                                            4.624                   
  WHO pathology                         I (18)            1                        0.099--0.986                   0.0359   1       0, infty        0.0850
                                        II or III(69)     0.312                                                            infty                   
  PS                                    0 (73)            1                        0.476--6.503                   0.3902   1       0.252--5.250    0.8572
                                        1 or 2 (14)       1.760                                                            1.149                   
  RT dose primary                       \<70 (5)          1                        0.064--1.340                   0.0924   1       0, infty        0.4078
                                        ≥70 (81)          0.293                                                            infty                   
  RT dose LN                            \<70 (21)         1                        0.254--3.471                   0.9255   1       0.356--7.407    0.5279
                                        ≥70 (65)          0.940                                                            1.622                   
  Total dose of 5-FU                    \<12,000 (37)     1                        0.135--1.349                   0.1354   1       0.143--1.429    0.1657
                                        ≥12,000 (50)      0.427                                                            0.453                   
  Total dose of CDDP                    \<300 (38)        1                        0.210--2.024                   0.4560   1       0.096--1.060    0.0490
  ≥300 (49)                             0.652                                                                              0.319                   
  OTT[2](#tf7-2){ref-type="table-fn"}   \<87 (38)         1                        0.126--1.474                   0.1673   1       0.238--2.291    0.5986
                                        ≥87 (47)          0.431                                                            0.739                   

Hazard ratio.

Overall treatment time.

###### 

Results of the multivariate analysis of prognostic factors on locoregional and distant metastasis-free rates

                                         Locoregional-free rate   Distant metastasis-free rate                                     
  -------------------- ----------------- ------------------------ ------------------------------ -------- -------- --------------- ----------------------------------
  TNM primary          1 or 2 (52)       1                        0.897--10.370                  0.0740                            
                       3 or 4 (35)       3.051                                                                                     
  TNM LN               0 or 1 (33)       1                        0.531--11.913                  0.2454                            [2](#tf8-3){ref-type="table-fn"}
                       2 or 3 (54)       2.514                                                                                     
  Stage                IIB or III (58)                                                                    1        1.549--17.347   0.0076
                       IV (29)                                                                            5.184                    
  WHO pathology        I (18)            1                        0.074--0.901                   0.0336                            [3](#tf8-4){ref-type="table-fn"}
                       II or III(69)     0.258                                                                                     
  RT dose primary      \<70 (21)         1                        0.035--0.972                   0.0463                            
                       ≥70 (65)          0.183                                                                                     
  Total dose of 5-FU   \<12,000 (37)     1                        0.155--1.012                   0.0531                            
                       ≥12,000 (50)      0.396                                                                                     
  Total dose of CDDP   \<300 (38)                                                                         1        0.082--0.925    0.0369
                       ≥300 (49)                                                                          0.2762                   

Gender was not incorporated into the multivariate analysis because no events were observed in female.

Hazard ratio.

N classification was not incorporated into the multivariate analysis because no events were observed in N0 or N1 patients.

WHO histology classification was not incorporated into the multivariate analysis because no events were observed in WHO type I patients.

The LRF and DMF curves are shown in Figure[3](#fig03){ref-type="fig"}. In the univariate analysis, gender, T classification, and WHO histological classification had significant impacts on the LRF rate. In the multivariate analysis, the WHO histological classification and radiation dose in the nasopharynx had significant impacts on LRF rate.

![(A) Actuarial locoregional recurrence-free (LRF) rates in all 87 patients with nasopharyngeal carcinoma by Kaplan--Meier method. A solid line: LRF curve. A broken line: 95% confidence interval. (B) Actuarial distant metastasis-free (DMF) rates in all 87 patients with nasopharyngeal carcinoma by Kaplan--Meier method. A solid line: DMF curve. A broken line: 95% confidence interval.](cam40004-1186-f3){#fig03}

In the univariate analysis, N classification, stage, and total CDDP dose had significant impacts on the DMF rate. In the multivariate analysis, stage, total CDDP dose, N classification, and WHO histological classification had significant impacts on the DMF rate.

Discussion
==========

IGS 0099 was considered a landmark for NPC treatment [@b7]. However, 3 courses of AC were administered after concurrent chemoradiotherapy (CCRT) in 55% of the patients. The objective of chemotherapy in NPC treatment is not only the improvement of local control but also the control of micrometastasis. In particular, the main role of AC is to control the latter, that is, distant metastasis. An analysis that combined data from NPC 9901 and NPC 9902, large-scale clinical trials involving the same treatment method as that outlined in IGS 0099, has indicated that AC was a factor related to the control of distant metastasis and that a particular correlation was noted with the 5-FU dose. When compared with 260 patients who received 0--1 cycle of adjuvant cycles, significant improvement was achieved in 167 patients with 3--4 cycles (*P* = 0.019) [@b10]. A meta-analysis also found that the involvement of CCRT in the control of distant metastasis was marginal (*P* = 0.04), but AC was a factor that exhibited a significant involvement (*P* = 0.009) [@b11]. In accordance, AC has been shown to be involved in the decrease of distant metastasis, but the results of a randomized controlled trial (RCT) comparing the treatment outcomes between a CCRT + AC group and a CCRT group and the results of a meta-analysis have not demonstrated any improvements in survival rates by the addition of AC [@b12],[@b13].

It has been proved that acute toxicity caused by CCRT reduces tolerance to AC, and neoadjuvant chemotherapy (NAC) + CCRT may be one future direction for treatment. Boscolo et al. reported the favorable long-term retrospective outcome after NAC+CCRT for locally advanced NPC [@b14]. In 2009, Hui et al. divided subjects into a group that underwent NAC involving 2 courses of CDDP (75 mg/m^2^) and docetaxel (75 mg/m^2^) every 3 weeks before undergoing CDDP (40 mg/m^2^) weekly as CCRT and a group that underwent CCRT with the same method. They compared these groups in a randomized phase II study and found that the 3-year OS rates were 94.1% and 67.7% for each group, respectively, and the 3-year PFS rates were 88.2% and 59.5%, respectively, indicating favorable outcomes for the NAC + CCRT group [@b15]. However, in 2013, Liang et al. conducted 11 RCTs comparing groups that underwent CCRT after NAC with those that underwent CCRT (with or without AC) in 1096 patients in a meta-analysis and found that PFS was improved, but no differences were observed for OS, locoregional failure-, and DMF survival [@b16]. Taxane (docetaxel or paclitaxel) has been confirmed in a meta-analysis as an effective medication for NAC in patients with advanced carcinomas of the head and neck [@b17]. In 7 of the 11 above-mentioned RCTs, taxane was used. These findings suggest that NAC increases the repopulation of the tumor and a buildup of chemoresistant tumor cells, resulting in decreased therapeutic results in CCRT [@b18].

At present, it is clear that CCRT improves the survival rates more than RT alone [@b12],[@b19]. The addition of AC after CCRT does not lead to a greater improvement in the survival rates compared with CCRT without AC [@b12],[@b13]. It is unclear whether the addition of NAC to CCRT improves survival rates compared with CCRT alone.

Compared with other carcinomas of the head and neck, NPC has high potential of distant metastasis [@b2]. Insufficient dose chemotherapy has not shown a benefit of control of distant metastasis compared with RT alone, which was suggested in Chan's study (RT concurrently with cisplatin at a dose of 40 mg/m^2^ weekly, *P* = 0.15) [@b21]. It is characteristic in NPC that a wider irradiation field is required during RT due to its progression pattern, and mucositis is a marked problem even when RT alone is performed. Considering these characteristics of NPC, ALCRT has two advantages compared with CCRT; a sufficient amount of antitumor agents can be administered to control distant metastasis, and it has the potential benefit in reducing acute toxicities [@b7],[@b9].

In Japan, the proportion of patients with WHO type I histopathology is approximately 20%, which is similar to that in North America and much higher than the rates in studies conducted in endemic regions [@b23]. It has proved to be less sensitive to RT and a significantly worse prognostic factor of OS and PFS [@b21],[@b22].

The ALCRT that we administered in the present study led to a 76% treatment completion rate, 78% 5-year OS, and 69% 5-year PFS. Compared with IGS 0099, the ALCRT was advantageous in these followings; a decreased total dose of CDDP (540 mg/m^2^ vs. 300 mg/m^2^), a shorter treatment period (130 days vs. 87 days), a higher treatment completion rate (53% vs. 76%), and a higher survival rate (78% 3y-OS in IGS 0099 vs. 78% 5y-OS in this study, 69% 3y-PFS in IGS 0099 vs. 69% 5y-PFS in this study). Considering that the percentage of patients classified as WHO type I, indicating a poor outcome, was 21%, the above-mentioned treatment outcomes appear to be extremely favorable.

The present study found that WHO type I histopathology recurred in 6 of the 18 patients, and that recurrence occurred from the irradiation field in all the patients. Therefore, as shown in Table[4](#tbl4){ref-type="table"}, in order to improve the local control rate, a higher dose RT in the form of intensity-modulated RT (IMRT) which is helpful for improving clinical results is necessary, especially for patients who exhibit WHO type I histopathology [@b23]. Recurrence occurred in 20 of the 69 patients who exhibited WHO type II and III histopathology. Twelve of these patients exhibited distant metastasis, suggesting the necessity of a stronger anti-cancer drug treatment or the combined use of molecular targeted therapy.

Conclusions
===========

This method of ALCRT yielded higher or at least similar survival rates and lower toxicities compared with CCRT. The future direction of ALCRT appears likely to involve the introduction of IMRT, and concerning anti-cancer drugs, the addition of taxane to conventional FP. We believe that ALCRT will be used in a controlled trial to compare therapeutic results with those of CCRT (with or without NAC).
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